A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors (NCT06427941)

🧪 Interventions in This Study

• BGB-B2033 (DRUG)
• Tislelizumab (DRUG)
• Bevacizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (48 Sites)

Showing the first 25 of 48 sites.

• City of Hope Phoenix Cancer Center — Goodyear, Arizona
• City of Hope National Medical Center — Duarte, California
• City of Hope Chicago Cancer Center — Zion, Illinois
• Memorial Sloan Kettering Cancer Center Mskcc — New York, New York
• Upmc Hillman Cancer Center(Univ of Pittsburgh) — Pittsburgh, Pennsylvania
• Scri Oncology Partners — Nashville, Tennessee
• The University of Texas Md Anderson Cancer Center — Houston, Texas
• Centro Gaucho Integrado de Oncologia Hospital Mae de Deus — Porto Alegre,
• Hospital Da Bahia — Salvador,
• Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto — São José do Rio Preto,
• Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira — São Paulo,
• Anhui Provincial Hospital — Hefei, Anhui
• Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality
• Mengchao Hepatobiliary Hospital of Fujian Medical University — Fuzhou, Fujian
• Zhujiang Hospital of Southern Medical University — Guangzhou, Guangdong
• Nanfang Hospital of Southern Medical University — Guangzhou, Guangdong
• Guangxi Medical University Cancer Hospital Wuxiang Branch — Nanning, Guangxi
• The Fourth Hospital of Hebei Medical University — Shijiazhuang, Hebei
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
• Union Hospital of Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei
• Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology — Wuhan, Hubei
• Hunan Cancer Hospital — Changsha, Hunan
• The Affiliated Hospital of Xuzhou Medical University — Xuzhou, Jiangsu
• The Second Affiliated Hospital of Nanchang University — Nanchang, Jiangxi
• The Second Affiliated Hospital of Nanchang Universityhongjiaozhou Branch — Nanchang, Jiangxi

📞 Contact the Study Coordinator

Phone: (877) 828-5568

Email: clinicaltrials@beonemed.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Hepatocellular Carcinoma

• Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations — Los Angeles, California

Explore by condition: All Metastatic Hepatocellular Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.